Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "NDA"

3729 News Found

Glaukos receives EU MDR certification for iStent infinite
Medical Device | July 02, 2025

Glaukos receives EU MDR certification for iStent infinite

The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma


AbbVie to acquire Capstan Therapeutics for $2.1 billion
Biotech | July 01, 2025

AbbVie to acquire Capstan Therapeutics for $2.1 billion

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo


Moderna announces promising efficacy results from mRNA flu vaccine trial
Diagnostic Center | July 01, 2025

Moderna announces promising efficacy results from mRNA flu vaccine trial

mRNA-1010 demonstrated superior relative vaccine efficacy


Briefs: Neuland Laboratories and Granules India
Drug Approval | June 29, 2025

Briefs: Neuland Laboratories and Granules India

Granules India receives 1 observation from USFDA for Chantilly facility


Alembic announces USFDA final approval for single-dose vials
Drug Approval | June 29, 2025

Alembic announces USFDA final approval for single-dose vials

Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma


Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France
Biopharma | June 29, 2025

Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France

Extended lab space for product development, customer demos, and training


Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr
News | June 29, 2025

Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr

Acquisition to be followed by merger; strengthens Torrent’s IPM market presence


European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME
Drug Approval | June 28, 2025

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME


Biocon Biologics receives Health Canada approval for Yesafili
Drug Approval | June 27, 2025

Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data


Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation
News | June 27, 2025

Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation

Star Health Insurance is modernising its claims ecosystem to be future-ready